“The Da Vinci Health Group has been critical in helping us understand and evaluate our options around seeking FDA clearance for our digital health products. Audrey's guidance around the importance of creating a reimbursement strategy at the same time as we are doing our FDA planning has saved us months, if not years, of headaches and delays. Audrey and her team are able to serve as our regulatory and reimbursement subject matter experts, offering critical knowledge, advice, and support when we need it. Highly recommended. - COO, Digital Health Company”
“We engaged Da Vinci Health Group to help us with two of our FDA approved biologics. Our company was experiencing non-payment issues for both products, and Da Vinci Health Group provided us a roadmap to repair the coverage and reimbursement barriers. They went above and beyond in their analysis, providing us a new pathway to increase market acceptance due to recent changes in CMS policy. Their expertise in FDA, CMS, and healthcare market acceptance is unsurpassed. Senior Director Managed Care, NYSE Biologics Company”
“Da Vinci Health Group provided our French medical device start-up with an invaluable go-to-market reimbursement plan. Their work gave us critical information to build out our market entry plan into the United States, including market positioning, optimal pricing, and product growth opportunities. We highly recommend Audrey’s team of market access experts.” – CEO, Medical Device Company, Paris, France.
“We partnered with Da Vinci Health Group on global health economic positioning of our medical device for minimal invasive surgical procedures. Through global medical collaboration, Audrey and her team developed a health economic model that informed our product pricing and helped us prove the value of our device in specific minimally invasive surgeries. The result has offered our company a value-based healthcare approach that is customizable across multiple different country settings. Da Vinci Health Groups’ market access and health economic expertise can’t be overstated.” – Global Vice President Marketing, NYSE Medical Device Company.
“We recently partnered with Da Vinci Health Group on the reimbursement and healthcare economics portion of diligence we were performing on a potential acquisition. Our Executive Leadership Team and Board of Directors were impressed with the insight we gathered from Da Vinci Health Group. Reimbursement was a critical factor in the market dynamics and there was some uncertainty about the future state of reimbursement. Based on the work of Da Vinci, which was unbiased and factual, we felt very comfortable with the current and future reimbursement landscape. Based on their final report, where we once had concern, we now had a good handle on the risks. We eventually purchased the asset with this work playing a critical role in the decision making process. In addition, we had a very tight timeline and required quick turnaround. Audrey and her team were extremely collaborative and on time with all of their deliverables. – Global Vice President Business Development, NASDAQ traded Medical Device Company